Stay updated with breaking news from Roche Lucentis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products),...
/PRNewswire/ -- Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products),...
Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity) Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease. The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Unity shares were up about 9% in early trading Tuesday morning. The study of UBX1325 was conducted in pat...
Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029 ResearchAndMarkets.com's offering. Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF). The most frequently used anti-VEGF drugs are Roche/Genentech's humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron's fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to t...